Apr 19, 2021 | Main Page Post, Product News, Rejuvenair, SPRAY-CB
Boston, MA –April 19, 2021: CSA Medical, Inc., today announced that Wissam Abouzgheib, MD, chief of pulmonary medicine at Cooper University Health Care, Camden, New Jersey, has joined the SPRAY-CB Study investigating a new device treatment for COPD with Chronic...
Nov 23, 2020 | Main Page Post, Product News, Rejuvenair
The RejuvenAir System is designed to address the underlying cause of COPD with Chronic Bronchitis and enable rejuvenative healing of the airways BOSTON, Nov. 23, 2020 — CSA Medical, Inc., today announced metered cryospray utilizing the RejuvenAir® System for the...
Nov 11, 2020 | Main Page Post, Product News, Rejuvenair
This study will provide a scientific rationale for the remodeling response and clinical improvements identified in the feasibility study Boston, MA –November 11, 2020: CSA Medical, Inc., today announced that over half of the subjects in a 32 patient study,...
Oct 22, 2020 | Main Page Post, SPRAY-CB
The SPRAY-CB trial marks the first pivotal study of a medical device therapy targeting the underlying cause of Chronic Bronchitis. Boston,MA. – October 22, 2020: CSA Medical Inc., a developer of medical devices advancing the power of liquid nitrogen spray cryotherapy,...
Dec 4, 2019 | Main Page Post, Rejuvenair, SPRAY-CB
Published by Mass Device Medical Network CSA Medical announced this week that it won CE Mark approval for its RejuvenAir system for treating chronic obstructive pulmonary disease (COPD) with chronic bronchitis (CB). The RejuvenAir system that is designed to apply...
Dec 2, 2019 | Main Page Post
Published by RT Magazine Health officials in Europe OK’d CSA Medical’s cryotherapy system to treat chronic obstructive pulmonary disease (COPD) with chronic bronchitis. The system applies metered sprayed liquid nitrogen at -196 C to areas within the lungs through a...
